Two years after Viatris Inc. was established from the merger of Mylan Pharmaceuticals Inc. with Pfizer Inc.'s Upjohn business, the former generics company is getting ready to begin the second phase of its growth strategy, starting with the acquisition of two potential new growth levers in ophthalmology. Viatris announced on 7 November the acquisition of Oyster Point Pharma, Inc. and Famy Life Sciences, two eye care companies, for an aggregate of $700m to $750m in cash.
The two acquisitions mark an important inflection point for Viatris as the management team attempts to position the company to...